Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of ESSA Pharma Inc. during the specified Class Period of the upcoming lead plaintiff deadline on March 25, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought ESSA Pharma Inc. securities between December 12, 2023, and October 31, 2024, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5]. - The lead plaintiff must file a motion with the Court by March 25, 2025, to represent other class members in the litigation [2]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its performance in this area since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Case Allegations - The lawsuit alleges that ESSA Pharma Inc. failed to disclose critical information regarding the efficacy of masofaniten in combination with enzalutamide, misleading investors about its effectiveness in treating prostate cancer [4]. - It is claimed that the M-E Combination Study was unlikely to meet its primary endpoint, leading to overstated clinical and commercial prospects for masofaniten [4]. - The public statements made by the defendants were deemed materially false and misleading, resulting in investor damages when the true information became public [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Target Corporation common stock between August 26, 2022, and November 19, 2024, about the April 1, 2025, deadline to become a lead plaintiff in a class action lawsuit related to misleading statements made by Target regarding its ESG and DEI initiatives [1][4]. Group 1: Class Action Details - Investors who bought Target stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][6]. - The deadline to move the court to serve as lead plaintiff is April 1, 2025, with the lead plaintiff acting on behalf of other class members [2]. Group 2: Allegations Against Target - The lawsuit claims that Target misled investors with false statements about its ESG and DEI mandates, leading to customer boycotts following the 2023 LGBT-Pride Campaign [4]. - The negative impact of the Campaign resulted in a significant decline in Target's stock price, marking the first sales drop in six years [5]. - It is alleged that Target's CEO and Board did not disclose known risks associated with the 2023 and 2024 Campaigns, causing investors to purchase stock at artificially inflated prices [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Novo Nordisk A/S securities between November 2, 2022, and December 19, 2024, of the March 25, 2025, lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Novo Nordisk securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by March 25, 2025 [2]. - The lawsuit claims that during the Class Period, defendants made misleading statements regarding the phase 3 CagriSema study on obesity, particularly about the expected outcomes and the nature of the trial protocol [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [3]. - The firm has been recognized for its achievements, including the largest securities class action settlement against a Chinese company at the time and being ranked highly for the number of settlements [3]. Group 3: Case Specifics - The lawsuit alleges that defendants provided overly positive statements about the CagriSema study, including an expected minimum average weight loss of 25% for patients, while concealing material adverse facts about the trial's flexible dosing protocol [4].

Core Viewpoint - Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of UnitedHealth Group Incorporated in relation to a Department of Justice investigation into the company's billing practices [1] Group 1 - The investigation by Rosen Law Firm is focused on UnitedHealth Group's billing practices and the possible implications for its directors and officers [1] - Investors who own shares of UnitedHealth are encouraged to seek more information and can contact Rosen Law Firm directly [2] - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [3]

NEW YORK, March 5, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Innovative Industrial Properties, Inc. (NYSE: IIPR) between February 27, 2024 and December 19, 2024, both dates inclusive (the "Class Period"), of the important March 18, 2025 lead plaintiff deadline.So what: If you purchased IIPR securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Micron Technology, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline on March 10, 2025 [1] Group 1: Class Action Details - Investors who bought Micron common stock between September 28, 2023, and December 18, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - To serve as lead plaintiff, individuals must file a motion with the Court by March 10, 2025 [3] Group 2: Case Allegations - The lawsuit alleges that Micron's management made false and misleading statements regarding the demand for its products, particularly in consumer markets and for NAND products [5] - It is claimed that the defendants overstated the recovery and sustainability of demand for Micron's products, leading to materially false public statements [5] - The lawsuit asserts that when the true details became known, investors suffered damages [5] Group 3: Rosen Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Class A common stock of The Trade Desk, Inc. for the period between May 9, 2024, and February 12, 2025, due to alleged misleading statements and execution challenges related to the rollout of their AI tool, Kokai [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Trade Desk faced significant execution challenges in rolling out Kokai, which negatively impacted its business and revenue growth [5]. - Defendants allegedly made false statements regarding Trade Desk's business operations and prospects, which were materially misleading [5]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Investors wishing to join the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by April 21, 2025, to represent other class members [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].

Core Viewpoint - Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of UnitedHealth Group Incorporated in relation to a Department of Justice investigation into the company's billing practices [1]. Group 1 - The investigation by Rosen Law Firm focuses on UnitedHealth Group's compliance with fiduciary duties amid allegations regarding its billing practices [1]. - The firm encourages current shareholders of UnitedHealth to seek more information and participate in the investigation [2]. - Rosen Law Firm has a strong track record in securities class actions, having secured significant settlements for investors, including over $438 million in 2019 [3].